Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims reflect on-label classification and Gram-negative indications, but several scientific/clinical characterizations (mechanism, spectrum comparisons, cross-reactivity/allergy prescribing rationale, and “commonly used/targeted”) are not supported by the provided label excerpts.
Category Scores
Accurate Statements
Aztreonam is a monobactam antibiotic.
DESCRIPTION: "contains... aztreonam, a monobactam."
Aztreonam is used to treat certain serious Gram-negative bacterial infections.
INDICATIONS AND USAGE: "AZACTAM is indicated for the treatment... infections caused by susceptible Gram-negative microorganisms" (followed by specific infection types).
Aztreonam is a different beta-lactam subclass than penicillins and some cephalosporins.
DESCRIPTION: "monobactams... are structurally different from other beta-lactam antibiotics (eg, penicillins, cephalosporins...)"
Unsupported Statements
Aztreonam works by interfering with bacterial cell-wall synthesis.
No mechanism statement in the provided label excerpts.
Aztreonam's spectrum is not the same as many other beta-lactams used more broadly for both Gram-negative and Gram-positive organisms.
No spectrum comparison language in the provided label excerpts.
Clinicians typically assess allergy history carefully before using aztreonam.
No allergy-history prescribing guidance in the provided label excerpts.
Aztreonam has different typical coverage patterns compared with broader beta-lactams such as many penicillins, cephalosporins, or carbapenems.
No comparative coverage/pattern language in the provided label excerpts.
Aztreonam classification as a monobactam involves different cross-reactivity considerations that matter in prescribing.
No cross-reactivity/allergy precaution text in the provided label excerpts.
Contradictions
Important Omissions
No provided claim assessed against dosing/administration, contraindications, boxed warnings, or specific safety monitoring; relevant labeling safety elements are not addressed in the extracted claim set.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated unsupported claims are primarily mechanistic/classification or generalized clinical-use characterizations; no contraindication, dosing, or boxed-warning related assertions were included that could directly create unsafe prescribing based on the extracted set.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims introduce mechanism/spectrum/cross-reactivity and “common/targeted/reserved-use” characterizations that are not supported by the supplied label excerpts.
Suggested Improvement
Restrict statements to the provided label language (monobactam classification and indicated Gram-negative infections) or supply additional label sections (e.g., precautions/allergies/mechanism/susceptibility/spectrum) before asserting those details.